Premium
The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases
Author(s) -
Langsenlehner Tanja,
Langsenlehner Uwe,
Renner Wilfried,
Kapp Karin S.,
Krippl Peter,
Hofmann Günter,
Clar Heimo,
Pummer Karl,
Mayer Ramona
Publication year - 2007
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20682
Subject(s) - prostate cancer , oncology , medicine , genotype , prostate , cancer , single nucleotide polymorphism , radiation therapy , biology , gene , genetics
Background Death receptor 4, encoded by the TNFRSF10A gene, is an important mediator of apoptosis and its dysfunction may be related to cancer development and distant tumor spread. A single nucleotide polymorphism in TNFRSF10A (Glu228Ala, rs20576) within a conserved region of the extracellular cysteine‐rich domain of death receptor 4 has been associated with an increased risk for a variety of tumor entities. Aim of the present study was to evaluate the role of the TNFRSF10A polymorphism in metastatic progression of prostate cancer after radiation therapy. Methods We carried out a prospective study including 702 prostate cancer patients from the Austrian PROCAGENE (Prostate Cancer Genetics) study. Development of metastases was examined in regular follow‐up investigations. TNFRSF10A genotypes were determined by a 5′‐nuclease assay (TaqMan). Results Within a median follow‐up time of 10 months (range 0–60 months), 24 (3.4%) patients developed metastases. In a Cox regression model including age at diagnosis and risk group as potential confounders, carriage of an 228Ala allele was associated with a relative risk of 2.47 (95% CI 1.10–5.54; P = 0.028) for metastases. TNFRSF10A genotypes were not associated with tumor stage, grade, risk group or age at diagnosis. Conclusion We conclude that the TNFRSF10A Glu228Ala polymorphism may be a novel independent risk factor for prostate cancer metastases after radiation therapy. Prostate 68: 264–268, 2008. © Wiley‐Liss, Inc.